Comprehensive molecular profiling of lung adenocarcinoma

Adenocarcinoma of the lung is the leading cause of cancer death worldwide. Here we report molecular profiling of 230 resected lung adenocarcinomas using messenger RNA, microRNA and DNA sequencing integrated with copy number, methylation and proteomic analyses. High rates of somatic mutation were seen (mean 8.9 mutations per megabase). Eighteen genes were statistically significantly mutated, including RIT1 activating mutations and newly described loss-of-function MGA mutations which are mutually exclusive with focal MYC amplification. EGFR mutations were more frequent in female patients, whereas mutations in RBM10 were more common in males. Aberrations in NF1, MET, ERBB2 and RIT1 occurred in 13% of cases and were enriched in samples otherwise lacking an activated oncogene, suggesting a driver role for these events in certain tumours. DNA and mRNA sequence from the same tumour highlighted splicing alterations driven by somatic genomic changes, including exon 14 skipping in MET mRNA in 4% of cases. MAPK and PI(3)K pathway activity, when measured at the protein level, was explained by known mutations in only a fraction of cases, suggesting additional, unexplained mechanisms of pathway activation. These data establish a foundation for classification and further investigations of lung adenocarcinoma molecular pathogenesis.

• Publication year

  2014

• Venue

  Nature

• Publication date

  2014-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/nature13385PMID 25079552PMCID 4231481
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Discovery and saturation analysis of cancer genes across 21 tumor types

  2014cited by this paper
• Oncogenic RIT1 mutations in lung adenocarcinoma

  2014cited by this paper
• A Pan-Cancer Analysis of Transcriptome Changes Associated with Somatic Mutations in U2AF1 Reveals Commonly Altered Splicing Events

  2014cited by this paper
• Mutational heterogeneity in cancer and the search for new cancer genes

  2014cited by this paper
• New pathologic classification of lung cancer: relevance for clinical practice and clinical trials.

  2013cited by this paper
• Pattern discovery and cancer gene identification in integrated cancer genomic data

  2013cited by this paper
• Genomic landscape of non-small-cell lung cancer in smokers and never-smokers

  2013cited by this paper
• Mutational heterogeneity in cancer and the search for new cancer genes

  2013cited by this paper
• Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.

  2013cited by this paper
• Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples

  2013cited by this paper
• Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

  2012cited by this paper
• Comprehensive genomic characterization of squamous cell lung cancers

  2012cited by this paper
• The transcriptional landscape and mutational profile of lung adenocarcinoma

  2012cited by this paper
• Chipping away at the lung cancer genome

  2012cited by this paper
• Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.

  2012cited by this paper
• Integrated analysis of genetic and epigenetic alterations reveals CpG island methylator phenotype associated with distinct clinical characters of lung adenocarcinoma.

  2012cited by this paper
• Differential Pathogenesis of Lung Adenocarcinoma Subtypes Involving Sequence Mutations, Copy Number, Chromosomal Instability, and Methylation

  2012cited by this paper
• ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers

  2012influential reference
• International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

  2012cited by this paper
• Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer

  2012cited by this paper
• ROS1 rearrangements define a unique molecular class of lung cancers.

  2012cited by this paper
• Absolute quantification of somatic DNA alterations in human cancer

  2012cited by this paper
• Genomic landscape of non-small cell lung cancer in smokers and never-smokers.

  2012cited by this paper
• Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer Development

  2011cited by this paper
• International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

  2011cited by this paper
• Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

  2010cited by this paper
• Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer

  2010cited by this paper
• [Lung cancer in smokers and never-smokers].

  2009cited by this paper
• Somatic mutations affect key pathways in lung adenocarcinoma

  2008cited by this paper
• Frequent BRG1/SMARCA4–inactivating mutations in human lung cancer cell lines

  2008cited by this paper
• Characterizing the cancer genome in lung adenocarcinoma

  2007cited by this paper
• Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma

  2007cited by this paper
• Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts.

  2006cited by this paper
• Dysfunctional KEAP1–NRF2 Interaction in Non-Small-Cell Lung Cancer

  2006cited by this paper
• Somatic mutations lead to an oncogenic deletion of met in lung cancer.

  2006cited by this paper
• The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers.

  2005cited by this paper
• Athletics: Momentous sprint at the 2156 Olympics?

  2004cited by this paper
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004cited by this paper
• Gene-expression profiles predict survival of patients with lung adenocarcinoma

  2002cited by this paper
• Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung.

  2002cited by this paper
• TTF-1 Expression in Pulmonary Adenocarcinomas

  2002cited by this paper
• Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses

  2001cited by this paper
• Mga, a dual‐specificity transcription factor that interacts with Max and contains a T‐domain DNA‐binding motif

  1999cited by this paper
• Functional recognition of the 3′ splice site AG by the splicing factor U2AF35

  1999cited by this paper
• A novel gene, DXS8237E, lies within 20 kb upstream of UBE1 in Xp11.23 and has a different X inactivation status.

  1996cited by this paper
• Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines.

  1995cited by this paper
• p53: a frequent target for genetic abnormalities in lung cancer.

  1989cited by this paper
• Massachusetts Institute of Technology

  1964cited by this paper

• Counterfactual Understanding via Retrieval-aware Multimodal Modeling for Time-to-Event Survival Prediction

  2026cites this paper
• Multi-omics to study chronic respiratory diseases and viral infections

  2026cites this paper
• Kras G12C- and G12D-driven lung cancers differ in oncogenic potency, immunogenicity, and relapse after Kras inhibition in mouse models.

  2026cites this paper
• ITGA8 suppresses proliferation and metastasis of lung adenocarcinoma through the inhibition of glycolysis.

  2026cites this paper
• Translating spatial transcriptomic signatures in adenosquamous carcinoma into bulk prognostic biomarkers in lung adenocarcinoma: a bottom-up approach

  2026cites this paper
• Targeting Mesenchymal-Epidermal Transition (MET) Aberrations in Non-Small Cell Lung Cancer: Current Challenges and Therapeutic Advances

  2026cites this paper
• MoAGNN: a multi-omics hierarchical graph neural network for subtype classification and prognosis prediction in lung adenocarcinoma

  2026cites this paper
• Generalisation of automatic tumour segmentation in histopathological whole-slide images across multiple cancer types.

  2026cites this paper
• A multiplex, prime editing framework for identifying drug resistance variants at scale.

  2026cites this paper
• Innovative approaches for lung cancer screening and interception.

  2026cites this paper
• BCL2A1high CD8+ T Cells Are a Survival-Associated Predictor of Immune Checkpoint Blockade Response in Lung Adenocarcinoma

  2026cites this paper
• Harnessing microRNAs in lung cancer: The future of diagnosis and precision therapy.

  2026cites this paper
• Multi‐Omics Analysis Reveals the Molecular Subtypes and Confirmed the GREM1 as the Core Gene

  2026cites this paper
• Metabolic reprogramming-driven stratification and therapeutic targeting in lung adenocarcinoma: implications for prognosis and personalized treatment

  2026cites this paper
• Prolonged survival in EGFR exon 20 insertion mutant lung adenocarcinoma: case report of sequential osimertinib and furmonertinib with research trend analysis

  2026cites this paper
• Actionable driver gene alterations in early-stage non-small cell lung cancer: a review

  2026influential citation
• Integrative clinico-molecular analysis reveals actionable subtypes and biomarkers in lung adenocarcinoma

  2026cites this paper
• Multi-omics analysis and experiments validate the tumor-suppressive role of mitochondrial lipid metabolism gene ACSM5 in lung adenocarcinoma and its impact on the immune microenvironment

  2026cites this paper
• RET Fusion-Positive Lung Adenocarcinoma: Partner-Specific Clinicopathological Characteristics, Co-Mutation Profiles, and Implications for Targeted and Immunotherapy.

  2026cites this paper
• Reporte de caso: ALKOMA oculto o emergente en una paciente no fumadora con cáncer de pulmón de célula no pequeña metastásico

  2026cites this paper
• Transcriptomic Subtypes Are Associated with Clinical Outcomes for Patients with Lung Adenocarcinoma Who Have Never Smoked.

  2026cites this paper
• Identification of PANoptosis-related genes in lung cancer and investigation of their role mechanisms in the immune microenvironment.

  2026cites this paper
• Multiomics assessment of lung adenocarcinoma subtypes defined through tumor purity-adjusted DNA methylation

  2026influential citation
• Mitochondrial DNA methylation predicts immunotherapy response and prognosis in lung adenocarcinoma: evidence from scRNA-Seq and machine learning.

  2026cites this paper
• Dual Effect of EZH2 Gene Editing with CRISPR/Cas9 in Lung Cancer

  2026cites this paper
• Integrated and Comprehensive Diagnostics: An Emerging Paradigm in Precision Oncology

  2026cites this paper
• Progress and prospects of organoids in the pathogenesis of lung cancer and screening of antitumor drugs

  2026cites this paper
• Deciphering benzo[a]pyrene-induced lung adenocarcinoma mechanisms via bioinformatics analysis

  2026cites this paper
• Comprehensive characterization of AP-1 adaptor complex genes in lung cancer reveals AP1AR as a novel prognostic and therapeutic biomarker

  2026cites this paper
• When genetics meets immunology: the assessment of genetic and immunological backgrounds in advanced NSCLC patients treated with immunotherapy - preliminary study.

  2026cites this paper
• Liquid biopsy and tissue biopsy for the detection of EGFR mutations in patients with stage III non-small-cell lung cancer: an observational real-world study

  2026cites this paper
• Characterization of Korean Colorectal Cancer Reveals Novel Driver Gene and Clinically Relevant Mutations

  2026cites this paper
• NFATc3 Enhances DREAM Complex-Driven Transactivation

  2026cites this paper
• Panorama: a database for the oncogenic evaluation of somatic mutations in pan-cancer

  2026cites this paper
• Pulmonary Solid and Granular Adenocarcinomas Expressing HepPar1: Highly Aggressive Tumors Exhibiting Mitochondrial Adaptation to STK11 Mutations rather than Hepatoid Differentiation.

  2026cites this paper
• LaCoGSEA: Unsupervised deep learning for pathway analysis via latent correlation

  2026cites this paper
• Glucose deprivation drives LIF-dependent lung cancer

  2026cites this paper
• TGFB-inducible VASN (vasorin) promotes lysosomal acidification.

  2026cites this paper
• CHEK1 Expression Correlates with Tumor Progression in Lung Adenocarcinoma but Not in Squamous Cell Carcinoma.

  2026cites this paper
• Breaking resistance barriers: ensartinib as a milestone in anaplastic lymphoma kinase-driven non-small cell lung cancer therapy.

  2026cites this paper
• KIF18B Is Essential for Lung Adenocarcinoma Progression Through the E2F Transcriptional Network.

  2026cites this paper
• Biología molecular del cáncer de pulmón de célula no pequeña

  2026cites this paper
• Role of EGFR-TKIs in Nonmetastatic Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Comprehensive Review.

  2026cites this paper
• Discovery and Characterization of Divarasib (GDC-6036), a Potent Covalent Inhibitor of KRAS G12C.

  2026cites this paper
• A viable human lung cancer tissue collection (LCTC) to accelerate translational research.

  2026cites this paper
• Lightweight APU-Net: enabling medical image segmentation on physicians’laptops

  2026cites this paper
• Current Insights and Future Directions of Multiomic and Spatial-Omic Analysis in Non-Small Cell Lung Cancer.

  2026cites this paper
• CRTAC1 inhibits progression of lung adenocarcinoma by suppressing integrin/FAK signaling

  2026cites this paper
• Sortilin exhibits tumor suppressor-like activity by limiting EGFR transduction function

  2026cites this paper
• TNF-⍺-mediated myeloid-instructed CD14+CD4+ T cells are associated with poor survival in lung adenocarcinoma.

  2026cites this paper
• Interpretable deep learning model of circulating genomics for quantitative survival prediction in advanced non-small cell lung cancer.

  2026cites this paper
• Genomic landscape of stage 0-IA lung adenocarcinoma identified by on-site reflex targeted NGS.

  2026cites this paper
• Loss of BOK increases vulnerability of p53 deficient non-small cell lung cancer cells to ATR inhibition through its role in uridine metabolism.

  2026cites this paper
• A multimodal AI biomarker PATH-ORACLE improves prediction of recurrence in stage I lung adenocarcinoma

  2026cites this paper
• Mutational landscapes of brain metastases across various histological subtypes of lung cancer.

  2026cites this paper
• An alternative EGFR activation by patient-derived R252C mutation promotes cancer progression

  2026cites this paper
• APE1 promotes lung adenocarcinoma through G4-mediated transcriptional reprogramming of urea cycle metabolism

  2025cites this paper
• Strategies to Overcome Resistance to Osimertinib in EGFR-Mutated Lung Cancer

  2025cites this paper
• Lung Adenocarcinoma With Bone Metastases: Clinicogenomic Profiling and Insights Into Prognostic Factors

  2025cites this paper
• Shared Genomic Features Between Lung Adenocarcinoma and Type 2 Diabetes: A Bioinformatics Study

  2025cites this paper
• Amplified dosage of the NKX2-1 lineage transcription factor controls its oncogenic role in lung adenocarcinoma.

  2025cites this paper
• Routine Clinical Liquid Biopsy Testing for Solid Tumors Delivers the Promise of Minimally Invasive Detection of Genomic Variants With a Faster Turnaround Time

  2025cites this paper
• FLT3: A narrative review

  2025cites this paper
• Durable response to Olaparib in EGFR and somatic BRCA2-mutated lung adenocarcinoma with leptomeningeal metastases: a case report

  2025cites this paper
• Evaluation of molecular glue-induced neo-Protein-Protein Interaction with a cell lysate-based TR-FRET assay

  2025cites this paper
• Brain metastases lung adenocarcinoma patients with BRG1 loss have a grim prognosis, featuring unique morphological and methylation characteristics

  2025cites this paper
• Exploring the oncogenic role and prognostic value of CKS1B in human lung adenocarcinoma and squamous cell carcinoma

  2025cites this paper
• A tumor necrosis factor-α–responsive cryptic promoter drives overexpression of the human endogenous retrovirus ERVK-7

  2025cites this paper
• Deciphering lung adenocarcinoma evolution and the role of LINE-1 retrotransposition

  2025cites this paper
• Transitional CXCL14+ cancer‐associated fibroblasts enhance tumour metastasis and confer resistance to EGFR‐TKIs, revealing therapeutic vulnerability to filgotinib in lung adenocarcinoma

  2025cites this paper
• A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer

  2025cites this paper
• Case Report: A novel MET exon 14 skipping mutation after EGFR-TKI resistance in advanced lung adenocarcinoma and sustained clinical response to savolitinib

  2025cites this paper
• Whole-miRNome sequencing (WMS) - a panel for targeted sequencing of all human miRNA genes

  2025cites this paper
• SKA3 promotes lung adenocarcinoma progression via the EGFR/E2F1/SKA3/integrin β1 signaling loop

  2025cites this paper
• Analytical and Clinical Validation of Solo‐Test Driver: A Targeted Amplicon‐Based NGS Test‐System for FFPE and cfDNA Analysis in Clinical Oncology Setting

  2025cites this paper
• Uncovering the rewired IAP-JAK regulatory axis as an immune-dependent vulnerability of LKB1-mutant lung cancer

  2025cites this paper
• Mutation of SMARCA4 Induces Cancer Cell–Intrinsic Defects in the Enhancer Landscape and Resistance to Immunotherapy

  2025cites this paper
• EGFR-induced lncRNA TRIDENT promotes drug resistance in non–small cell lung cancer via phospho-TRIM28-mediated DNA damage repair

  2025cites this paper
• Single cell transcriptomic analysis reveals tumor immune infiltration by macrophage cells gene signature in lung adenocarcinoma

  2025cites this paper
• HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study

  2025cites this paper
• Immunogenic cell death signature predicts survival and reveals the role of VEGFA + Mast cells in lung adenocarcinoma

  2025cites this paper
• Multiplexed in vivo base editing identifies functional gene-variant-context interactions

  2025cites this paper
• Basic science and translational implications of current knowledge on neuroendocrine tumors

  2025cites this paper
• Integrating epidemiology and genomics data to estimate the prevalence of acquired cysteine drug targets in the U.S. cancer patient population

  2025cites this paper
• Lethal co-expression intolerance underlies the mutually exclusive expression of ASCL1 and NEUROD1 in SCLC cells

  2025cites this paper
• Survival benefit from abemaciclib in non–small cell lung cancer by Kirsten rat sarcoma–mutation gene expression subtype: retrospective analysis from the JUNIPER Trial

  2025cites this paper
• Translating premalignant biology to accelerate non-small-cell lung cancer interception

  2025cites this paper
• Baseline retinoblastoma transcriptional corepressor 1 (Rb1) functional inactivation is a pre-requisite but not sufficient for small-cell histological transformation in epidermal growth factor receptor (EGFR) mutant lung adenocarcinomas post-tyrosine kinase inhibitor therapy

  2025cites this paper
• Tumour-wide RNA splicing aberrations generate actionable public neoantigens

  2025cites this paper
• MET variants with activating N‐lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulation

  2025cites this paper
• Utilizing Nanoparticles to Overcome Anti-PD-1/PD-L1 Immunotherapy Resistance in Non-Small Cell Lung cancer: A Potential Strategy

  2025cites this paper
• The role of MKI67 in the regulation of 60S pre-ribosome nucleolar export, transcripts, energy supply, and apoptosis

  2025cites this paper
• Multi-omics analysis of epigenetic dysregulation reveals clinical heterogeneity and evaluates the immunotherapeutic potential of lung adenocarcinoma

  2025cites this paper
• Integrative spatial analysis reveals tumor heterogeneity and immune colony niche related to clinical outcomes in small cell lung cancer.

  2025cites this paper
• Robust prognostic biomarkers and a risk prediction model specific to EGFR-mutated lung adenocarcinoma patients via multicohort meta-analysis

  2025cites this paper
• Structure-Based Design of New LSD1/EGFRL858R/T790M Dual Inhibitors for Treating EGFR Mutant NSCLC Cancers.

  2025cites this paper
• Mapping the genetic landscape of iron metabolism uncovers the SETD2 methyltransferase as a modulator of iron flux

  2025cites this paper
• Trastuzumab deruxtecan in HER2 overexpressing non-small cell lung cancer (NSCLC)

  2025cites this paper
• Cytologic Diagnoses of Lung Adenocarcinoma With Concomitant Metastasis From a Different Primary: A Case Series

  2025cites this paper
• Prognostic and predictive effects of TP53 co-mutation in patients with non-small cell lung cancer with rare treatable driver mutations.

  2025cites this paper